Key Drivers
- Strong FCF
- Moderate leverage
- Intangible-heavy
AIAI Summary
UFPT has become a cash‑generative med‑tech contract manufacturer whose valuation upside is now a binary execution-and-capacity story—investors should treat it as a capacity/execution bet and closely monitor AJR normalization, successful qualification/fulfillment of the large customer expansion, and reclaiming $240–242 resistance as the primary near‑term triggers for rerating.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong FCF
- •Moderate leverage
- •Intangible-heavy
UFPT combines strong margins, robust FCF and healthy liquidity with moderate leverage, but carries significant intangible assets and a premium valuation that tighten downside protection.
Price Behavior
Key Price Behavior Insights:
- •Downtrend momentum
- •Support broken
- •High volatility
Over the last month UFPT has fallen sharply (closed $191.05 on 2026-03-20, ≈18% down from ~$233 on 2026-02-20), broke the $202–$205 support cluster, hit a new low and left $240–$242 as the key reclamation target.
Large swings from the $240s to low $190s over the last month indicate elevated short-term volatility
Sentiment & News
Key News Insights:
- •Strong FY25
- •Cautious demand
- •Cost cuts/invest
UFPT delivered record FY25 results and upbeat earnings momentum while parent UFPI faces flat-to-down 2026 demand but is pursuing $60M cost cuts, $300–$350M investments and benefits from a strong net-cash position.
UFPT's momentum should support its share performance near term, while UFPI's proactive cost reductions and cash-rich balance sheet may cushion earnings amid softer demand
Similar Companies in Healthcare
Other companies in the same sector with AI ratings